| Nov 1 |
Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
|
| Oct 31 |
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
|
| Oct 31 |
Exelixis price target raised to $36 from $33 at Piper Sandler
|
| Oct 30 |
Q3 2024 Exelixis Inc Earnings Call
|
| Oct 30 |
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
|
| Oct 30 |
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
| Oct 30 |
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
|
| Oct 30 |
Exelixis, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Oct 30 |
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
|
| Oct 29 |
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
|
